Contact a Rep
CONTACT A REP
Interested in connecting with an ANI Pharmaceuticals representative?

Fill out the request form below if you wish to be contacted with more information on Cortrophin Gel.

This form is for healthcare professionals only. If you are a patient looking to contact customer service, please call 1-800-434-1121 or email info@anipharmaceuticals.com.

* = Required

I confirm and agree to the following:*

I am a licensed US healthcare professional. I understand that this information may be used by ANI Pharmaceuticals and its affiliates and partners or third parties working on behalf of ANI Pharmaceuticals to contact me. I agree that the personal information I provide may be used by ANI Pharmaceuticals, or other companies acting on its behalf, to contact me via mail, email, or otherwise provide me with information about educational materials, market research, products, and services concerning Cortrophin Gel. I give my permission for ANI Pharmaceuticals to use my information for reasonable business purposes as permitted or required by law. Neither ANI Pharmaceuticals nor the companies working on its behalf may sell or rent my personal information except for as set forth in the ANI Pharmaceuticals Privacy Policy.

* = Required

ABOUT CORTROPHIN GEL

Cortrophin Gel is an FDA-approved repository corticotropin injection in the ACTH drug class1
Cortrophin Gel is a naturally sourced, purified corticotropin (ACTH) that is made up of a complex mixture of ACTH, ACTH-related peptides, and other natural pituitary-derived peptides1
Cortrophin Gel is compliant with the United States Pharmacopeia (USP) monograph for Repository Corticotropin Injection1

5 mL

1 mL

For intramuscular
or subcutaneous use.

Vial sizes are not to scale.

Available in 2 Vial Sizes

Cortrophin Gel is available in a 1-mL or 5-mL vial, both containing 80 units per mL.1 Either vial size can be shipped directly to the patient via a specialty pharmacy. Additionally, the 1-mL vial can be purchased from distributors for in-office use.

0.5 mL

1 mL

0.5 mL

For subcutaneous
use only.

Prefilled syringe sizes
are not to scale.

Available as Prefilled Syringes

Cortrophin Gel is available as single-dose prefilled syringes 0.5 mL and 1 mL, providing less steps to administer.1 Either size of the prefilled syringe can be shipped directly to the patient via a specialty pharmacy.

Discard and Storage information

Cortrophin Gel Dosing & Administration

Dosing and frequency should be individualized according to medical condition, severity of the disease, and initial response of the patient.1

Dosing

IM=intramuscularly; SC=subcutaneously.

Please monitor your patients for side effects if Cortrophin Gel is administered more than 40 units daily, because chronic administration of more than 40 units daily may be associated with uncontrollable adverse effects.1

Standard tests for verification of adrenal responsiveness to corticotropin may utilize as much as 80 units as a single injection or one or more injections of a lesser dosage. Verification tests should be performed prior to treatment with corticotropins. The test should utilize the route(s) of administration proposed for treatment. Following verification, dosage should be individualized according to the disease under treatment and the general medical condition of each patient.1

Advise patients and/or caregivers to read the appropriate Instructions for Use, depending on whether you have prescribed the vial or the prefilled syringe of Cortrophin Gel.

*Dosage and schedule per UpToDate Inc. Lexi-Drugs™, which is an evidence-based drug compendium recommended by Centers for Medicare and Medicaid Services.2
†Dosage and schedule per the Merative Micromedex DRUGDEX®, which is an evidence-based drug compendium recommended by Centers for Medicare and Medicaid Services.3

IM=intramuscularly; SC=subcutaneously.

Dosing guide iconDosing guide icon
Condition-Specific Dosing Guide

Download and print this convenient dosing guide to help facilitate individual dosing conversations with your patients.

Dosing Guide

Storage

refrigerate

Store Purified Cortrophin Gel vials and prefilled syringes refrigerated at 36° to 46°F (2° to 8°C)1

room

Purified Cortrophin Gel vials and prefilled syringes may be stored at room temperature between 68° to 77°F (20° to 25°C) for up to 24 hours1

When to discard

6monts

Discard 1-mL vials 6 months after first use (top seal punctured) or by the expiration date stamped on the vial, whichever occurs first1

28 days

Discard 5-mL vials 28 days after first use (top seal punctured) or by the expiration date stamped on the vial, whichever occurs first1

single use

Discard Purified Cortrophin Gel prefilled syringes immediately after use or by the expiration date stamped on the syringe1

Prescribing
Cortrophin Gel

Access important
enrollment information.

Prescribe & Enroll
Patient Support & Reimbursement

See how Cortrophin In Your Corner, our dedicated patient support program, can help patients throughout the treatment process.

EXPLORE SUPPORT
Provider & Patient
Resources

Explore downloadable resources, as well as educational materials for your appropriate patients, including injection guides.

Get Resources

References: 1. Cortrophin Gel. Prescribing information. 2. Corticotropin Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. Accessed March 9, 2026. https://online.lexi.com 3. Corticotropin. Merative Micromedex DRUGDEX®. Accessed March 9, 2026. https://www.micromedexsolutions.com

Indications
Important Safety Information
Expand ISI
IndicationsExpand ISI

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly. It is indicated for:

Cortrophin Gel is indicated for:

  • Acute exacerbations of multiple sclerosis.
  • Short-term administration as an adjunctive therapy during an acute episode or exacerbation in rheumatoid arthritis, including juvenile rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; and acute gouty arthritis.
  • Exacerbations or as maintenance therapy in select cases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).
  • Severe erythema multiforme (Stevens-Johnson syndrome) and severe psoriasis.
  • Atopic dermatitis and serum sickness.
  • Severe acute and chronic allergic and inflammatory conditions affecting the eye and its adnexa, such as allergic conjunctivitis, keratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation.
  • Symptomatic sarcoidosis.
  • Inducing a diuresis or remission of proteinuria due to nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.
Important Safety InformationExpand ISI
Contraindications
  • Cortrophin Gel is contraindicated for intravenous administration.
  • Cortrophin Gel is contraindicated in patients who have any of the following conditions: scleroderma; osteoporosis; systemic fungal infections; ocular herpes simplex; recent surgery; history of or the presence of a peptic ulcer; congestive heart failure; hypertension; primary adrenocortical insufficiency; adrenocortical hyperfunction; or sensitivity to proteins derived from porcine sources.
Warnings and Precautions
  • Infections: Corticotropin therapy may increase susceptibility to infections and may mask the symptoms of infections.
  • Adrenal insufficiency: Prolonged corticotropin therapy can increase the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by gradually reducing the corticotropin dosage. Hormone therapy should be reinstituted if stressful situations arise during discontinuation.
  • Elevated blood pressure, salt and water retention, and hypokalemia: Corticotropin can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium or calcium.
  • Masking symptoms of other diseases: Corticotropin may only suppress signs and symptoms of chronic disease without altering the natural course of disease.
  • Psychiatric reactions: Psychic derangements may appear when corticotropin is used, ranging from euphoria, insomnia, mood swings, personality changes, and depression to psychosis. Existing conditions may be aggravated.
  • Ophthalmic reactions: Prolonged use of corticotropin may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves.
  • Immunogenicity potential: Prolonged administration of Cortrophin Gel may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Cortrophin Gel activity.
  • Vaccination: Patients should not be vaccinated against smallpox while on corticotropin therapy. Other immunizations should be undertaken with caution due to possible neurologic complications and lack of antibody response.
  • Use in patients with hypothyroidism and cirrhosis: There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis.
  • Use in patients with latent tuberculosis or tuberculin reactivity: Closely observe for reactivation of the disease.
  • Comorbid diseases: Corticotropin should be used with caution in patients with diabetes, abscess, pyogenic infections, diverticulitis, renal insufficiency, and myasthenia gravis.
  • Growth and development: Carefully observe growth and development of infants and children on prolonged corticotropin therapy.
  • Acute gouty arthritis: Treatment of acute gouty arthritis should be limited to a few days. Conventional concomitant therapy should be administered during corticotropin treatment and for several days after it is stopped.
  • Drug interactions: Aspirin should be used cautiously with corticotropin in hypoprothrombinemia.
  • Pregnancy: Since fetal abnormalities have been observed in animals, Cortrophin Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Adverse Reactions

Adverse reactions for Cortrophin Gel include fluid or sodium retention; muscle weakness; osteoporosis; peptic ulcer with possible perforation and hemorrhage; injection site reactions; impaired wound healing; hypertension; convulsions; headache; development of Cushingoid state; suppression of growth in children; anaphylaxis (anaphylactic shock, urticaria, respiratory compromise, edema); and weight gain. These are not all the adverse reactions reported with Cortrophin Gel.

Please see full Prescribing Information.

Indications

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly. It is indicated for:

Cortrophin Gel is indicated for:

  • Acute exacerbations of multiple sclerosis.
  • Short-term administration as an adjunctive therapy during an acute episode or exacerbation in rheumatoid arthritis, including juvenile rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; and acute gouty arthritis.
  • Exacerbations or as maintenance therapy in select cases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).
  • Severe erythema multiforme (Stevens-Johnson syndrome) and severe psoriasis.
  • Atopic dermatitis and serum sickness.
  • Severe acute and chronic allergic and inflammatory conditions affecting the eye and its adnexa, such as allergic conjunctivitis, keratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation.
  • Symptomatic sarcoidosis.
  • Inducing a diuresis or remission of proteinuria due to nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.
Important Safety InformationContraindications
  • Cortrophin Gel is contraindicated for intravenous administration.
  • Cortrophin Gel is contraindicated in patients who have any of the following conditions: scleroderma; osteoporosis; systemic fungal infections; ocular herpes simplex; recent surgery; history of or the presence of a peptic ulcer; congestive heart failure; hypertension; primary adrenocortical insufficiency; adrenocortical hyperfunction; or sensitivity to proteins derived from porcine sources.
Warnings and Precautions
  • Infections: Corticotropin therapy may increase susceptibility to infections and may mask the symptoms of infections.
  • Adrenal insufficiency: Prolonged corticotropin therapy can increase the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by gradually reducing the corticotropin dosage. Hormone therapy should be reinstituted if stressful situations arise during discontinuation.
  • Elevated blood pressure, salt and water retention, and hypokalemia: Corticotropin can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium or calcium.
  • Masking symptoms of other diseases: Corticotropin may only suppress signs and symptoms of chronic disease without altering the natural course of disease.
  • Psychiatric reactions: Psychic derangements may appear when corticotropin is used, ranging from euphoria, insomnia, mood swings, personality changes, and depression to psychosis. Existing conditions may be aggravated.
  • Ophthalmic reactions: Prolonged use of corticotropin may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves.
  • Immunogenicity potential: Prolonged administration of Cortrophin Gel may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Cortrophin Gel activity.
  • Vaccination: Patients should not be vaccinated against smallpox while on corticotropin therapy. Other immunizations should be undertaken with caution due to possible neurologic complications and lack of antibody response.
  • Use in patients with hypothyroidism and cirrhosis: There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis.
  • Use in patients with latent tuberculosis or tuberculin reactivity: Closely observe for reactivation of the disease.
  • Comorbid diseases: Corticotropin should be used with caution in patients with diabetes, abscess, pyogenic infections, diverticulitis, renal insufficiency, and myasthenia gravis.
  • Growth and development: Carefully observe growth and development of infants and children on prolonged corticotropin therapy.
  • Acute gouty arthritis: Treatment of acute gouty arthritis should be limited to a few days. Conventional concomitant therapy should be administered during corticotropin treatment and for several days after it is stopped.
  • Drug interactions: Aspirin should be used cautiously with corticotropin in hypoprothrombinemia.
  • Pregnancy: Since fetal abnormalities have been observed in animals, Cortrophin Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Adverse Reactions

Adverse reactions for Cortrophin Gel include fluid or sodium retention; muscle weakness; osteoporosis; peptic ulcer with possible perforation and hemorrhage; injection site reactions; impaired wound healing; hypertension; convulsions; headache; development of Cushingoid state; suppression of growth in children; anaphylaxis (anaphylactic shock, urticaria, respiratory compromise, edema); and weight gain. These are not all the adverse reactions reported with Cortrophin Gel.

Please see full Prescribing Information.